Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT-216 MAD in Friedreich Ataxia
NCT05573698Phase 1Completed
- Sponsor
- Design Therapeutics
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Friedreich ataxia (FA) comparing Multiple Dose: DT-216 with Placebo (2 arms). Primary endpoint: Safety Measure at 60 days. Started Sep 2022; status: completed.
02
Drugs
DT-216
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT05573698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05573698.